News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
492,312 Results
Type
Article (11837)
Company Profile (142)
Press Release (480423)
Multimedia
Podcasts (52)
Webinars (7)
Section
Business (169946)
Career Advice (390)
Deals (26319)
Drug Delivery (25)
Drug Development (55054)
Employer Resources (34)
FDA (10118)
Job Trends (8950)
News (243310)
Policy (18951)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (579)
Accelerated approval (27)
ADA (20)
Adcomms (7)
Allergies (97)
Alliances (33775)
ALS (106)
Alzheimer's disease (1003)
Antibody-drug conjugate (ADC) (296)
Approvals (10663)
Artificial intelligence (333)
ASCO (185)
Autoimmune disease (220)
Automation (28)
Bankruptcy (268)
Best Places to Work (7170)
BIO (36)
BIOSECURE Act (3)
Biosimilars (116)
BioSpace Insights (24)
Biotechnology (90)
Bladder cancer (153)
Brain cancer (30)
Breast cancer (525)
Cancer (3781)
Cardiovascular disease (253)
Career advice (316)
Career pathing (6)
CAR-T (181)
CDC (20)
Celiac Disease (1)
Cell therapy (501)
Cervical cancer (38)
Clinical research (48931)
Collaboration (1272)
Commercialization (3)
Compensation (1427)
Complete response letters (37)
COVID-19 (1600)
CRISPR (66)
C-suite (803)
Cystic fibrosis (87)
Data (5662)
Decentralized trials (1)
Denatured (4)
Depression (103)
Dermatology (61)
Diabetes (349)
Diagnostics (4237)
Digital health (38)
Diversity (2)
Diversity, equity & inclusion (11)
Drug discovery (167)
Drug pricing (74)
Drug shortages (3)
Duchenne muscular dystrophy (188)
Earnings (73935)
Editorial (18)
Employer branding (7)
Employer resources (33)
Events (88235)
Executive appointments (734)
FDA (12751)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (20)
Frontotemporal dementia (24)
Funding (962)
Gene editing (138)
Generative AI (13)
Gene therapy (370)
GLP-1 (408)
Government (1460)
Grass and pollen (2)
Guidances (284)
Healthcare (9645)
Hematology (95)
HIV (57)
Huntington's disease (25)
IgA nephropathy (64)
Immunology and inflammation (123)
Immuno-oncology (64)
Indications (157)
Infectious disease (1822)
Inflammatory bowel disease (136)
Inflation Reduction Act (7)
Influenza (90)
Intellectual property (252)
Interviews (51)
IPO (12480)
IRA (21)
Job creations (2123)
Job search strategy (299)
JPM (14)
Kidney cancer (17)
Labor market (11)
Layoffs (114)
Leadership (4)
Legal (5386)
Licensing (5)
Liver cancer (46)
Longevity (15)
Lung cancer (523)
Lymphoma (265)
Machine learning (27)
Management (10)
Manufacturing (559)
Marketing (7)
MASH (124)
Medical device (8681)
Medtech (8818)
Mergers & acquisitions (14867)
Metabolic disorders (828)
mRNA (134)
Multiple sclerosis (104)
NASH (5)
Neurodegenerative disease (232)
Neuropsychiatric disorders (42)
Neuroscience (1863)
NextGen: Class of 2026 (3265)
Non-profit (899)
Now hiring (2)
Obesity (318)
Opinion (63)
Ovarian cancer (160)
Pain (176)
Pancreatic cancer (196)
Parkinson's disease (202)
Partnered (11)
Patents (487)
Patient recruitment (505)
Peanut (31)
People (42459)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (15830)
Phase 2 (21839)
Phase 3 (15017)
Pipeline (7110)
Policy (95)
Postmarket research (1594)
Preclinical (6636)
Press Release (34)
Prostate cancer (200)
Psychedelics (14)
Radiopharmaceuticals (193)
Rare diseases (625)
Real estate (3127)
Recruiting (15)
Regulatory (15348)
Reports (17)
Research institute (687)
Resumes & cover letters (59)
Rett syndrome (41)
RNA editing (5)
RSV (69)
Schizophrenia (103)
Series A (165)
Series B (130)
Service/supplier (5)
Sickle cell disease (73)
Special edition (9)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2172)
Stomach cancer (3)
Supply chain (55)
Tariffs (34)
The Weekly (47)
Vaccines (736)
Venture capital (33)
Weight loss (159)
Women's health (79)
Date
Last 7 days (525)
Last 30 days (1443)
Last 365 days (19605)
2026 (11943)
2025 (19862)
2024 (23447)
2023 (26994)
2022 (35462)
2021 (38229)
2020 (34194)
2019 (23792)
2018 (17964)
2017 (19322)
2016 (18450)
2015 (24524)
2014 (21876)
2013 (18312)
2012 (20411)
2011 (20658)
2010 (20451)
Location
Africa (283)
Alabama (73)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (18642)
Australia (2188)
California (11813)
Canada (3100)
China (591)
Colorado (478)
Connecticut (409)
Delaware (208)
Europe (26982)
Florida (1781)
Georgia (370)
Hawaii (3)
Idaho (46)
Illinois (700)
India (46)
Indiana (315)
Iowa (14)
Japan (401)
Kansas (100)
Kentucky (31)
Louisiana (27)
Maine (25)
Maryland (1233)
Massachusetts (7835)
Michigan (305)
Minnesota (560)
Mississippi (5)
Missouri (79)
Montana (21)
Nebraska (11)
Nevada (113)
New Hampshire (60)
New Jersey (2625)
New Mexico (12)
New York (2817)
North Carolina (1260)
North Dakota (4)
Northern California (5909)
Ohio (273)
Oklahoma (14)
Oregon (18)
Pennsylvania (2255)
Puerto Rico (20)
Rhode Island (32)
South America (456)
South Carolina (76)
South Dakota (1)
Southern California (4894)
Tennessee (117)
Texas (1901)
United States (38610)
Utah (356)
Vermont (1)
Virginia (155)
Washington D.C. (42)
Washington State (913)
West Virginia (2)
Wisconsin (75)
492,312 Results for "pfizer inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate
Pfizer scraps Seagen-developed ADC for solid tumors
Just weeks after Pfizer’s Seagen-acquired antibody-drug conjugate sigvotatug vedotin failed a Phase 3 non-small cell lung cancer study, the big pharma has quietly culled another program being developed by the ADC specialist.
July 15, 2026
·
1 min read
·
Gabrielle Masson
Earnings
Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
Asked on a second quarter earnings call if Pfizer could direct more money to M&A amid a feeding frenzy across the pharma industry, CEO Albert Bourla defended his strategy.
August 4, 2026
·
1 min read
·
Annalee Armstrong
Lung cancer
Pfizer delivers ‘disappointing’ late-stage lung cancer data for ADC from $43B Seagen buy
Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.
June 23, 2026
·
2 min read
·
Tristan Manalac
Breast cancer
Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 billion in sales.
March 17, 2026
·
1 min read
·
Annalee Armstrong
Earnings
Pfizer is a 2029 story but Q126 lays foundation for growth
A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.
May 5, 2026
·
3 min read
·
Annalee Armstrong
Cardiovascular disease
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival
Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.
May 12, 2026
·
2 min read
·
Tristan Manalac
Patents
Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug that generated $3.8 billion in the U.S. last year.
April 29, 2026
·
2 min read
·
Nick Paul Taylor
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with muscle-invasive bladder cancer, even those eligible for cisplatin treatment.
March 2, 2026
·
2 min read
·
Tristan Manalac
Earnings
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
February 3, 2026
·
4 min read
·
Annalee Armstrong
Pipeline
Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer
Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns.
April 24, 2026
·
2 min read
·
Tristan Manalac
1 of 49,232
Next
